K W Rammohan

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. pmc Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study
    K W Rammohan
    Department of Neurology, Ohio State University, 449 Means Hall, 1654 Upham Drive, Columbus, Ohio 43210, USA
    J Neurol Neurosurg Psychiatry 72:179-83. 2002
  2. pmc Cerebrospinal fluid in multiple sclerosis
    Kottil W Rammohan
    Clinical and Experimental Neuroimmunology, Department of Neurology, The Ohio State University, Columbus, Ohio 43221 USA
    Ann Indian Acad Neurol 12:246-53. 2009
  3. ncbi request reprint Axonal injury in multiple sclerosis
    Kottil W Rammohan
    Department of Neurology, Ohio State University, Room 449 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
    Curr Neurol Neurosci Rep 3:231-7. 2003
  4. doi request reprint Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008
  5. doi request reprint A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
    Andrew D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Ann Neurol 68:494-502. 2010
  6. ncbi request reprint Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla
    A Kangarlu
    Department of Radiology, The Ohio State University College of Medicine, Columbus, Ohio, USA
    AJNR Am J Neuroradiol 28:262-6. 2007
  7. doi request reprint Emerging multiple sclerosis oral therapies
    Kottil W Rammohan
    The MS Center, Columbus, OH 43221, USA
    Neurology 74:S47-53. 2010
  8. ncbi request reprint Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study
    Kottil W Rammohan
    Neurology 65:1995-7; author reply 1995-7. 2005
  9. ncbi request reprint Issues and practices in multiple sclerosis
    Jack S Burks
    Washoe Institute of Neurosciences, University of Nevada School of Medicine, Reno 89509, USA
    Neurorehabil Neural Repair 16:307-20. 2002
  10. pmc A dinucleotide deletion in CD24 confers protection against autoimmune diseases
    Lizhong Wang
    Division of Immunotherapy, Department of Surgery, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, United States of America
    PLoS Genet 3:e49. 2007

Collaborators

Detail Information

Publications11

  1. pmc Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study
    K W Rammohan
    Department of Neurology, Ohio State University, 449 Means Hall, 1654 Upham Drive, Columbus, Ohio 43210, USA
    J Neurol Neurosurg Psychiatry 72:179-83. 2002
    ..To assess the efficacy and safety of modafinil for the treatment of fatigue in multiple sclerosis (MS)...
  2. pmc Cerebrospinal fluid in multiple sclerosis
    Kottil W Rammohan
    Clinical and Experimental Neuroimmunology, Department of Neurology, The Ohio State University, Columbus, Ohio 43221 USA
    Ann Indian Acad Neurol 12:246-53. 2009
    ..OBJECTIVE, MATERIALS AND METHODS: To review the current state of knowledge of changes in the CSF in multiple sclerosis...
  3. ncbi request reprint Axonal injury in multiple sclerosis
    Kottil W Rammohan
    Department of Neurology, Ohio State University, Room 449 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
    Curr Neurol Neurosci Rep 3:231-7. 2003
    ..The axon will undoubtedly remain the focus of our attention regarding research on MS now and in the future...
  4. doi request reprint Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008
    ..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)...
  5. doi request reprint A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
    Andrew D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Ann Neurol 68:494-502. 2010
    ..The current study was designed to confirm efficacy and further define safety and pharmacodynamics...
  6. ncbi request reprint Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla
    A Kangarlu
    Department of Radiology, The Ohio State University College of Medicine, Columbus, Ohio, USA
    AJNR Am J Neuroradiol 28:262-6. 2007
    ..Our purpose was to examine if imaging at 8T can detect plaques in cortical gray matter (CGM) not evident at 1.5T...
  7. doi request reprint Emerging multiple sclerosis oral therapies
    Kottil W Rammohan
    The MS Center, Columbus, OH 43221, USA
    Neurology 74:S47-53. 2010
    ..In this report, we weigh the beneficial outcomes of these compounds against their risks of adverse effects...
  8. ncbi request reprint Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study
    Kottil W Rammohan
    Neurology 65:1995-7; author reply 1995-7. 2005
  9. ncbi request reprint Issues and practices in multiple sclerosis
    Jack S Burks
    Washoe Institute of Neurosciences, University of Nevada School of Medicine, Reno 89509, USA
    Neurorehabil Neural Repair 16:307-20. 2002
    ..This review summarizes the main points of this discussion and is intended to serve as a reference for neurologists involved in the care of patients with MS...
  10. pmc A dinucleotide deletion in CD24 confers protection against autoimmune diseases
    Lizhong Wang
    Division of Immunotherapy, Department of Surgery, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, United States of America
    PLoS Genet 3:e49. 2007
    ..The dinucleotide deletion significantly reduced the stability of CD24 mRNA. Our results demonstrate that a destabilizing dinucleotide deletion in the 3' UTR of CD24 mRNA conveys significant protection against both MS and SLE...